SEC Form 10-K filed by Marker Therapeutics Inc.
$MRKR
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/5/2025 | $8.00 | Buy | Canaccord Genuity |
| 2/17/2022 | $3.00 → $1.00 | Buy → Neutral | Roth Capital |
Canaccord Genuity initiated coverage of Marker International with a rating of Buy and set a new price target of $8.00
Roth Capital downgraded Marker Therapeutics from Buy to Neutral and set a new price target of $1.00 from $3.00 previously
Piper Sandler initiated coverage of Marker Therapeutics with a rating of Overweight and set a new price target of $6.00
8-K - Marker Therapeutics, Inc. (0001094038) (Filer)
8-K - Marker Therapeutics, Inc. (0001094038) (Filer)
8-K - Marker Therapeutics, Inc. (0001094038) (Filer)
Results from safety lead-in stage of Marker's Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope spreading New T cell manufacturing process for MT-401 and other product candidates designed to improve potency, increase antigen specificity and diversity and significantly reduce manufacturing time Company announces clinical updates, including plans to file additional INDs by year end, with clinical trials in solid tumors and blood cancers to be initiated in 2023 Company to host conference call and webcast at 5:00 p.m. EST today HOUSTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, In
HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Wednesday, February 16, 2022 at 5:00 p.m. EST to provide an update on the Company's clinical programs, manufacturing processes and pipeline. The webcast will be accessible in the Investors section of the Company's website at www.markertherapeutics.com. Individuals can participate in the conference call by dialing 877-869-3847 (domestic) or 201-68
HOUSTON, Nov. 10, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021. "This quarter, we continued our momentum in advancing Marker's Phase 2 trial of MT-401, Marker's lead MultiTAA-specific T cell therapy, for the treatment of post-transplant acute myeloid leu
4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced a collaboration with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), for current good manufacturing practice (cGMP) manufacturing of MT-601, Marker's lead Multi-Antigen Recognizing (MAR)-T cell therapy. MT-601 is currently being investigated in the Phase 1 APOLLO study in patients with lymphoma who relapsed after anti-CD19 chimeric antigen receptor (C
HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a live webcast produced by Demy-Colton in collaboration with the WBB Research Institute titled "Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?". The virtual event is scheduled to take place on May 28, 2025, at 11:00 a.m. EDT. This one-hour virtual event will feature insights from leading voices in the cell therapy space, f
HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity's Horizons in Oncology Virtual Conference. Dr. Vera will join company executives and key opinion leaders to discuss innovations in T cell-based immunotherapies as part of a panel focused on the future of CAR-T and other novel approaches in solid tumors. Panel Participation Details: EventCG Horizons in Onc